← board
EBS
distress 1/10 · well-funded / low risk$7.54-1%today-46% from 52w high
emergentbiosolutions.com900 employeesFounded 1998Gaithersburg, MDDrug Manufacturers - Specialty & Generic
Revenue
$156M
Liquidity
$160M
Runway
—
Shares 1y
-3%
Price & events
-37.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.5%
1D
-2.0%
1W
-5.9%
1M
-6.8%
3M
-36.9%
6M
-1.6%
1Y
-39.6%
2Y
-88.3%
5Y
-91.9%
All
Overview
- Market Cap
- $389.04M
- Enterprise Value
- $802.34M
- Volume
- 43.18K
- 52 Week Range
- $5.63 – $13.90
- Total Shares
- 51.60M
- Float Shares
- 49.38M
- Short %
- 20.21%
- % Held by Insiders
- 3.85%
- % Held by Institutions
- 86.92%
- RVOL
- 0.05x
- Beta
- 2.34
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 10
- 2026-08-05earningsEarningsEarnings releaseyahoo
- 2026-06-26partnershipACAM2000 · Received $52.7M contract modification from ASPR for ACAM2000 supply, option year 7.SEC 8-K
- January 14, 2026conferencedata presentationsecondary44th Annual J.P. Morgan Healthcare Conference presentationSEC 8-K
- 2025-12-12fda agreementraxibacumab · FDA approval for drug product manufacturing at Winnipeg siteSEC 8-K
- 2025-09-05partnershipACAM2000 · Contract modification from ASPR for supply of ACAM2000, valued at $56M, delivery by Dec 31, 2025.SEC 8-K
- 2025-08-29partnershipCYFENDUS · BARDA modification for $30M additional dosesSEC 8-K
- 2025-03-10partnershipEmergent entered agreement to sell Baltimore-Bayview drug substance manufacturing facility to Syngene for ~$36.5 million, retaining rights to future manufacturing services.SEC 8-K
- 2025-01-14partnershipKLOXXADO (Naloxone HCl) Nasal Spray 8 mg · Emergent obtained commercial rights in US/Canada from Hikma; Hikma to continue manufacturingSEC 8-K
- 2024-12-13partnershipBioThrax · Contract modification with DoD/JPEO-CBRND for supply valued at $20M, effective Dec 13, 2024.SEC 8-K
- 2024-12-12partnershipCYFENDUS (AV7909) · Contract modification with BARDA for additional doses valued at $50M, effective Dec 12, 2024.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-03-09HC Wainwright & Co.Buy
- 2025-12-16HC Wainwright & Co.Buy
- 2025-09-03HC Wainwright & Co.Buy
- 2025-04-01HC Wainwright & Co.Buy
- 2025-03-21HC Wainwright & Co.Buy
- 2025-03-04HC Wainwright & Co.Buy
Competitors
- none identified
Recent news
- 2026-07-23Emergent BioSolutions to report Q2 2026 results on August 5 - scanx.trade
- 2026-07-22Emergent BioSolutions offers live webcast for Aug. 5 results call - Stock Titan
- 2026-07-16Emergent BioSolutions (EBS) AGM 2026 Summary - Quartr
- 2026-07-16Emergent BioSolutions (EBS) Q3 2024 earnings summary - Quartr
- 2026-07-16Emergent BioSolutions (EBS) Proxy filing Summary - Quartr
- 2026-07-16Emergent BioSolutions (EBS) Proxy filing Summary - Quartr
- 2026-07-16Emergent BioSolutions (EBS) Q1 2026 earnings summary - Quartr
- 2026-07-16Emergent BioSolutions (EBS) Proxy filing Summary - Quartr
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.